Technetium (99mTc) tilmanocept
Pharmaceutical drug
From Wikipedia, the free encyclopedia
Technetium (99mTc) tilmanocept, sold under the brand name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent used to locate lymph nodes which may be draining from tumors, and assist doctors in locating lymph nodes for removal during surgery.[6]
| |
| Clinical data | |
|---|---|
| Trade names | Lymphoseek |
| Other names | technetium Tc 99m tilmanocept |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intradermal, subcutaneous, intratumor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 1.75 to 3.05 hours at injection site |
| Identifiers | |
| |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | (C6H10O5)n(C19H28N4O9S99mTc)3–8(C13H24N2O5S2)12–20(C5H11NS)0–17 |
| Molar mass | 15,281–23,454 g/mol[4] |
The most common side effects include pain or irritation at the injection site.[7]
It was approved for medical use in the United States in March 2013,[4][7] and in the European Union in November 2014.[5]
Medical uses
In the US, technetium (99mTc) tilmanocept is indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in people with solid tumors for which this procedure is a component of intraoperative management; and guiding sentinel lymph node biopsy using a handheld gamma counter in people with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.[4][7]
In the EU, technetium (99mTc) tilmanocept is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adults with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity.[5] External imaging and intraoperative evaluation may be performed using a gamma detection device.[5]
